Adjuvant Therapy for Postmenopausal Women with Stage IIIA Breast Cancer

Introduction to Adjuvant Chemotherapy

The National Comprehensive Cancer Network recommends adjuvant chemotherapy for stage IIIA breast cancer, regardless of hormone receptor status, due to the anatomic extent of the disease 1
The sequential regimen of taxane followed by anthracycline-cyclophosphamide is a well-established standard approach for stage IIIA disease, as endorsed by the Journal of the National Comprehensive Cancer Network 2, 3

The European Society for Medical Oncology suggests that dose-dense or intensive chemotherapy regimens benefit from prophylactic G-CSF support to prevent severe neutropenia, with pegfilgrastim being a suitable option 3

The European consensus guidelines strongly recommend bisphosphonates, such as zoledronic acid, for postmenopausal women with early breast cancer at intermediate or high risk of recurrence, with a recommended dose of 4 mg IV every 6 months 4, 5
The use of zoledronic acid has been shown to reduce bone metastases and improve survival in postmenopausal women, with a 25% relative risk reduction for invasive disease-free survival and 26% reduction in death risk, as demonstrated in the AZURE trial 4, 6

The National Comprehensive Cancer Network guidelines support sequential anthracycline-taxane regimens for stage III breast cancer, while the European Society for Medical Oncology endorses this chemotherapy approach for high-risk early breast cancer 2, 3
The St. Gallen consensus recommends chemotherapy for stage III disease, and the European expert panel achieved >80% consensus that adjuvant bisphosphonates should be considered in postmenopausal women with early breast cancer 1, 4

The proposed sequence of chemotherapy followed by endocrine therapy is appropriate for ER+/PR+ disease, with extended endocrine therapy (5-10 years) with aromatase inhibitor indicated for postmenopausal patients with stage III disease 1, 2, 3
Zoledronic acid, if used, should be initiated at the start of adjuvant therapy and continued for 3-5 years, with adequate calcium and vitamin D supplementation and dental examination before initiation to minimize osteonecrosis of the jaw risk 4, 5

The National Comprehensive Cancer Network (NCCN) recommends that postmenopausal women with hormone receptor-positive breast cancer receive adjuvant endocrine therapy following chemotherapy, as it is a category 1 recommendation 7, 8, 9.
The American College of Clinical Oncology and other international guidelines support the use of aromatase inhibitors as the preferred endocrine therapy for postmenopausal women with stage IIIA disease, which should be administered for 5-10 years 10.

The NCCN explicitly states that adjuvant chemotherapy should be followed by endocrine therapy in patients with hormone receptor-positive disease, as category 1 evidence 7, 8.
Aromatase inhibitor therapy is mandatory for postmenopausal women with hormone receptor-positive breast cancer, even with minimal ER/PR expression of 1-5%, and should be administered for 5-10 years 9, 10.
The use of zoledronic acid as an adjunct to endocrine therapy can be considered for postmenopausal women with early breast cancer at intermediate or high risk of recurrence, but it is not a substitute for endocrine therapy 11.

Radiation therapy to the chest wall and regional lymph nodes is recommended for patients with stage IIIA disease and positive nodes, given the high risk of recurrence 7, 8.

Endocrine therapy should begin after completion of chemotherapy, with aromatase inhibitor as the preferred agent over tamoxifen in postmenopausal women 9, 10.
If zoledronic acid is added, ensure adequate calcium and vitamin D supplementation, baseline dental examination, and periodic bone mineral density monitoring 11.

The NCCN guidelines explicitly state to "consider adjuvant bisphosphonate therapy for risk reduction of distant metastasis" in postmenopausal women with early breast cancer at intermediate-to-high risk 12.
Multiple international guidelines (ESMO, St. Gallen consensus) support bisphosphonate use in postmenopausal women with early breast cancer at intermediate-to-high risk 12.